Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I

Abstract

The present editorial is a "Part I," focusing on the recent advance of cancer treatment. 1,[6][7][8][9][10] Conventionally, treatment opinions have limited to surgery, radiotherapy, and chemotherapy before. Although the majority of them, if localized tumor or early-stage cancers are diagnosed, can be successfully managed by three aforementioned strategies, there is no doubt that for a substantial number of women presenting with persistent, recurrent and/or metastatic cancers the prognosis is extremely poor, and rarely these advanced cancer patients could have the median overall survival more than 1 year, suggesting that new prognostic information-or personalized biomarkers-driven approach treatment is urgently needed.Herein, we are happy to introduce the exciting works from the "Winners" of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei. In this part I, Dr. Wu and his colleagues won this award for their work entitled "Immunoprofile of adenosquamous carcinoma in gastric cancer" which was published in the June issue of 2023 JCMA. 1 The authors attempted to investigate the immune profile of the rare subtype of gastric cancer in Taiwan to look for the optimal treatment modality. Among the data pool of all gastric cancers, gastric adenosquamous cancer (GASC) presented 0.35% (14/4034) reflecting its real rarity. Their study protocols included the recently very important biomarkers, such as p40, human epidermal growth factor receptor 2 (HER2), Epstein-Barr virus-encoded RNA (EBER), programmed death-ligand 1 (PD-L1) combined positive score (CPS), V-Raf murine sarcoma viral oncogene homolog B (BRAF), and DNA mismatch repair (MMR) proteins (eg, MutL Homolog 1 [MLH1], MutS homolog